Surrozen Publishes Study In 'eLife' Highlihgitng Potential To Enhance Wnt-Signal Activation In Targeted SWEETS Bispecific Antibodies

6/12/24 8:32:38 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches

Surrozen's current SWEETS bispecific antibodies are unique TPD technologies

Results demonstrated that the two new ASGR-targeted SWEETS bispecific antibodies enhanced Wnt-signal activation through the unique TPD platform

Date	Price Target	Rating	Analyst
1/30/2025	$32.00	Buy	H.C. Wainwright
1/3/2025	$45.00	Neutral → Buy	Guggenheim
10/11/2021	$11.00	Buy	B of A Securities
9/15/2021	$20.00	Buy	Guggenheim
9/7/2021	$19.00	Buy	Stifel

Recent Analyst Ratings for
$SRZN